WO2003085089A3 - Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same - Google Patents

Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same Download PDF

Info

Publication number
WO2003085089A3
WO2003085089A3 PCT/US2003/009260 US0309260W WO03085089A3 WO 2003085089 A3 WO2003085089 A3 WO 2003085089A3 US 0309260 W US0309260 W US 0309260W WO 03085089 A3 WO03085089 A3 WO 03085089A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
methods
relates
compositions
interleukin
Prior art date
Application number
PCT/US2003/009260
Other languages
French (fr)
Other versions
WO2003085089A2 (en
Inventor
Scott Greenfeder
Jose Corvalan
Original Assignee
Schering Corp
Abgenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP03716836A priority Critical patent/EP1527100B1/en
Priority to AT03716836T priority patent/ATE435239T1/en
Priority to CA2479927A priority patent/CA2479927C/en
Priority to AU2003220525A priority patent/AU2003220525A1/en
Priority to DE60328195T priority patent/DE60328195D1/en
Priority to SI200331661T priority patent/SI1527100T1/en
Application filed by Schering Corp, Abgenix Inc filed Critical Schering Corp
Priority to JP2003582268A priority patent/JP2005530490A/en
Priority to DK03716836T priority patent/DK1527100T3/en
Priority to MXPA04009418A priority patent/MXPA04009418A/en
Publication of WO2003085089A2 publication Critical patent/WO2003085089A2/en
Publication of WO2003085089A3 publication Critical patent/WO2003085089A3/en
Priority to HK05103968.7A priority patent/HK1070907A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human anti-IL-5 antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IL-5 antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IL-5 antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IL-5 antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
PCT/US2003/009260 2002-03-29 2003-03-27 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same WO2003085089A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AT03716836T ATE435239T1 (en) 2002-03-29 2003-03-27 HUMAN MONOCLONAL ANTIBODIES TO INTERLEUKIN-5 AND THESE COMPREHENSIVE METHODS AND COMPOSITIONS
CA2479927A CA2479927C (en) 2002-03-29 2003-03-27 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
AU2003220525A AU2003220525A1 (en) 2002-03-29 2003-03-27 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
DE60328195T DE60328195D1 (en) 2002-03-29 2003-03-27 HUMAN MONOCLONAL ANTIBODIES TO INTERLEUKIN-5 AND THESE COMPREHENSIVE METHODS AND COMPOSITIONS
SI200331661T SI1527100T1 (en) 2002-03-29 2003-03-27 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
EP03716836A EP1527100B1 (en) 2002-03-29 2003-03-27 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
JP2003582268A JP2005530490A (en) 2002-03-29 2003-03-27 Human monoclonal antibody and method for interleukin-5 and composition comprising the same
DK03716836T DK1527100T3 (en) 2002-03-29 2003-03-27 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising the same
MXPA04009418A MXPA04009418A (en) 2002-03-29 2003-03-27 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same.
HK05103968.7A HK1070907A1 (en) 2002-03-29 2005-05-12 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36904402P 2002-03-29 2002-03-29
US60/369,044 2002-03-29

Publications (2)

Publication Number Publication Date
WO2003085089A2 WO2003085089A2 (en) 2003-10-16
WO2003085089A3 true WO2003085089A3 (en) 2005-03-10

Family

ID=28791919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009260 WO2003085089A2 (en) 2002-03-29 2003-03-27 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same

Country Status (16)

Country Link
US (2) US7141653B2 (en)
EP (1) EP1527100B1 (en)
JP (2) JP2005530490A (en)
CN (1) CN1326879C (en)
AT (1) ATE435239T1 (en)
AU (1) AU2003220525A1 (en)
CA (1) CA2479927C (en)
CY (1) CY1109423T1 (en)
DE (1) DE60328195D1 (en)
DK (1) DK1527100T3 (en)
ES (1) ES2327830T3 (en)
HK (1) HK1070907A1 (en)
MX (1) MXPA04009418A (en)
PT (1) PT1527100E (en)
SI (1) SI1527100T1 (en)
WO (1) WO2003085089A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895266B2 (en) 2000-10-06 2014-11-25 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP2005530490A (en) * 2002-03-29 2005-10-13 シェーリング　コーポレイション Human monoclonal antibody and method for interleukin-5 and composition comprising the same
EP1572106B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AR046833A1 (en) * 2003-11-10 2005-12-28 Schering Corp ANTI-INTERLEUQUINA ANTIBODIES-10
PT2311873T (en) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc M-csf-specific monoclonal antibody and uses thereof
CA2776682A1 (en) * 2004-05-14 2005-12-01 Optimer Pharmaceuticals, Inc. Tiacumicin b compound
ATE541585T1 (en) * 2004-10-28 2012-02-15 Kyowa Hakko Kirin Co Ltd ANTIBODIES TO IL-5 RECEPTOR FOR USE IN THE TREATMENT OF ENDOMETRIOSIS.
US8030003B2 (en) * 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
EP1913028B1 (en) * 2005-07-28 2015-03-04 Novartis AG Use of antibody to m-csf
JP5457671B2 (en) * 2005-07-28 2014-04-02 ノバルティス アーゲー M-CSF specific monoclonal antibody and use thereof
JP2009508494A (en) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Compositions comprising receptor-binding protein (RAP) variants specific for proteins comprising CR and uses thereof
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US7981414B2 (en) * 2005-12-20 2011-07-19 Cephalon Australia Pty Ltd Anti-inflammatory dAb
JP5259423B2 (en) 2006-02-01 2013-08-07 セファロン・オーストラリア・ピーティーワイ・リミテッド Domain antibody construct
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
WO2008011571A1 (en) * 2006-07-21 2008-01-24 Amgen Inc. Polypeptides with reduced susceptibility to oxidation and methods of making
JP4781929B2 (en) 2006-07-25 2011-09-28 富士通株式会社 Electronics
JP4842040B2 (en) 2006-07-25 2011-12-21 富士通株式会社 Electronics
JP5148079B2 (en) 2006-07-25 2013-02-20 富士通株式会社 Heat exchanger for liquid cooling unit, liquid cooling unit and electronic equipment
JP2008027370A (en) 2006-07-25 2008-02-07 Fujitsu Ltd Electronic device
CN101626783A (en) * 2006-08-04 2010-01-13 诺华有限公司 EPHB3-specific antibody and its application
EP3415532A1 (en) 2006-08-18 2018-12-19 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
US20080132688A1 (en) * 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
BRPI0717601A2 (en) * 2006-10-24 2013-10-22 Trubion Pharmaceuticals Inc IMPROVED IMMUNGLYPROTEINS MATERIALS AND METHODS
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
JP5645409B2 (en) 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー Method for treating IL-1β related diseases
TW201307390A (en) 2007-02-02 2013-02-16 Amgen Inc Hepcidin, hepcidin antagonists and methods of use
CA2682578C (en) 2007-04-03 2015-05-26 Oxyrane Uk Limited Glycosylation of molecules
SI2152290T1 (en) * 2007-04-30 2014-09-30 Glaxosmithkline Llc Methods for administering anti-il-5 antibodies
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP3330292A1 (en) * 2007-08-21 2018-06-06 Amgen, Inc Human c-fms antigen binding proteins
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
ES2962777T3 (en) 2007-11-15 2024-03-21 Amgen Inc Antioxidant-stabilized aqueous antibody formulation for parenteral administration
PL2391650T3 (en) 2007-12-20 2015-03-31 Xoma Us Llc Methods for the treatment of gout
JP5701064B2 (en) 2008-01-25 2015-04-15 アムジエン・インコーポレーテツド Ferroportin antibody and method of use thereof
NZ587292A (en) 2008-03-04 2012-09-28 Pfizer Ltd Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
US9834600B2 (en) * 2008-03-28 2017-12-05 Glaxosmithkline Llc Methods of treatment of eosinophilic bronchitis with an anti-IL-5 antibody
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
US8128932B2 (en) * 2009-08-17 2012-03-06 Shanghai Aosaiersi Biotech Co., Ltd. Anti-VEGFR monoclonal antibody, method of making and uses thereof
ES2912569T3 (en) 2009-08-28 2022-05-26 Teva Pharmaceuticals Int Gmbh Methods of treating visceral pain by administering antagonistic antibodies directed against calcitonin gene-related peptide
EP2480888B1 (en) 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CN104651428A (en) 2009-09-29 2015-05-27 根特大学 Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP2013511272A (en) 2009-11-19 2013-04-04 オキシレイン ユーケー リミテッド Yeast strain producing mammalian-like complex N-glycans
US20130096281A1 (en) 2010-01-21 2013-04-18 Oxyrane Uk Limited Methods and compositions for displaying a polypeptide on a yeast cell surface
WO2012042387A2 (en) 2010-09-29 2012-04-05 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
WO2012042386A2 (en) 2010-09-29 2012-04-05 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
ES2720136T3 (en) * 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
US9745373B2 (en) 2011-05-20 2017-08-29 Alderbio Holdings Llc Anti-CGRP compositions and use thereof
JP6189832B2 (en) 2011-05-20 2017-08-30 アルダーバイオ・ホールディングズ・エルエルシー Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute diarrhea
CN103702685B (en) 2011-05-20 2017-12-15 奥尔德生物控股有限责任公司 Anti- CGRP antibody and antibody fragment are used to prevent or suppress photophobia in subject in need, especially migraineur or detest the purposes of light
SG10201902706VA (en) 2011-06-03 2019-04-29 Xoma Technology Ltd Antibodies specific for tgf-beta
AU2012272559C1 (en) 2011-06-23 2017-04-20 Children's Hospital Medical Center Molecular diagnostic panel of eosinophilic gastrointestinal disorders
CN104144946A (en) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 Methods for treating acne
PT2809681T (en) 2012-01-31 2019-02-18 Regeneron Pharma Anti-asic1 antibodies and uses thereof
BR112014022624A2 (en) 2012-03-15 2017-07-11 Oxyrane Uk Ltd Methods and Materials for Treatment of Pompe Disease
ES2701093T3 (en) 2012-08-21 2019-02-20 Sanofi Biotechnology Methods to treat or prevent asthma by administering an IL-4R antagonist
US20190178879A1 (en) * 2012-08-23 2019-06-13 Stemcell Technologies Canada Inc. Compositions and methods for rapid and reversible biomolecular labeling
WO2014058389A1 (en) 2012-10-12 2014-04-17 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
TWI755763B (en) 2013-06-04 2022-02-21 美商再生元醫藥公司 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
TWI634900B (en) 2013-07-11 2018-09-11 再生元醫藥公司 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
RU2704999C2 (en) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Method of treating skin infection by administering antagonist il-4r
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
IL247853B (en) 2014-03-21 2022-08-01 Teva Pharmaceuticals Int Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2016014761A (en) 2014-05-16 2017-05-25 Amgen Inc Assay for detecting th1 and th2 cell populations.
JP6861630B2 (en) 2014-11-14 2021-04-21 サノフィ・バイオテクノロジー How to treat chronic sinusitis with nasal polyps by administration of IL-4R antagonist
WO2016079219A1 (en) 2014-11-19 2016-05-26 Koninklijke Philips N.V. Diagnostic method employing hnl
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
CN105315371B (en) * 2015-03-05 2018-05-29 北京百特美博生物科技有限公司 Anti-human IL-17 monoclonal antibodies
US10167334B2 (en) 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
WO2017024285A2 (en) 2015-08-06 2017-02-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
EP3402572B1 (en) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
JP7148493B2 (en) 2016-08-01 2022-10-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
EP3506931A1 (en) 2016-09-01 2019-07-10 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018045117A1 (en) * 2016-09-01 2018-03-08 The Regents Of The University Of Colorado, A Body Corporate Methods of treating eosinophilic gastrointestinal diseases
CN109952314A (en) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 Treat intractable migraine
MX2019003543A (en) 2016-09-28 2019-06-17 Xoma Us Llc Antibodies that bind interleukin-2 and uses thereof.
TWI784988B (en) 2016-12-01 2022-12-01 美商再生元醫藥公司 Methods of treating inflammatory conditions
US11111292B2 (en) * 2016-12-23 2021-09-07 Cephalon, Inc. Anti-IL-5 antibodies
SG11201908328XA (en) 2017-03-14 2019-10-30 Amgen Inc Control of total afucosylated glycoforms of antibodies produced in cell culture
EP3634434A4 (en) * 2017-05-12 2021-06-09 The Regents of The University of California Treating and detecting dysbiosis
CN110913887A (en) 2017-06-06 2020-03-24 葛兰素史克有限责任公司 Biopharmaceutical compositions and methods for pediatric patients
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
PT3515465T (en) 2017-08-18 2024-03-04 Regeneron Pharma Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
CN111065651B (en) * 2017-09-29 2023-07-14 江苏恒瑞医药股份有限公司 IL-5 antibodies, antigen binding fragments thereof and medical uses thereof
RU2698048C2 (en) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" Monoclonal antibody to il-5rα
EP3703818B1 (en) 2017-10-30 2023-11-01 Sanofi Biotechnology Il-4r antagonist for use in a method for treating or preventing asthma
CN109942706A (en) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 Monoclonal antibody, preparation method and use in conjunction with people IL-5
JP2021508719A (en) * 2017-12-29 2021-03-11 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ Gene therapy for eosinophil disorders
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
CA3093853A1 (en) 2018-03-26 2019-10-03 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
KR20210010518A (en) 2018-05-13 2021-01-27 리제너론 파아마슈티컬스, 인크. How to treat atopic dermatitis by administering an IL-4R inhibitor
CN113366016B (en) * 2018-12-12 2022-12-16 上海开拓者生物医药有限公司 Monoclonal antibody for resisting human interleukin 5 (IL-5) and application thereof
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
WO2020191346A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
WO2021026203A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
US20220349898A1 (en) 2019-09-26 2022-11-03 Amgen Inc. Methods of producing antibody compositions
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN114075282B (en) * 2020-08-20 2024-01-02 南京融捷康生物科技有限公司 IL-5 binding molecules, methods of making and uses thereof
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
TW202317614A (en) 2021-06-07 2023-05-01 美商安進公司 Using fucosidase to control afucosylation level of glycosylated proteins
CA3233279A1 (en) 2021-10-05 2023-04-13 Amgen, Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267779A3 (en) 1986-11-10 1990-01-17 Schering Biotech Corporation Human pleiotropic immune factor and muteins thereof
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR960002183B1 (en) 1988-11-03 1996-02-13 쉐링 코포레이션 Pharmaceutical composition for prevention or reducing
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3068180B2 (en) * 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド Generation of heterologous antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
JPH06506105A (en) * 1990-08-29 1994-07-14 ファーミング　ビーブイ Homologous recombination in mammalian cells
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DE69229477T2 (en) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methods for the production of humanized antibodies
JPH05244982A (en) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
KR0150060B1 (en) * 1992-02-06 1998-08-17 에릭 에스. 딕커 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
ES2301158T3 (en) 1992-07-24 2008-06-16 Amgen Fremont Inc. XENOGENIC ANTIBODY PRODUCTION.
US5625125A (en) * 1994-08-09 1997-04-29 Dnx Biotherapeutics Phospholipase A2 expressing transgenic animals
US5643763A (en) * 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
CZ297045B6 (en) * 1994-12-23 2006-08-16 Smithkline Beecham Corporation Rodent neutralizing monoclonal antibody, process for its preparation, composition in which it is comprised and method of use thereof , hybridoma and antibody produced thereby, Fab fragment, complementarity determining region, nucleic acid molecule an
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
KR100479146B1 (en) * 1995-04-21 2005-05-16 셀 제네시스, 인코포레이티드 Generation of Large Genomic DNA Deletions
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) * 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR20080059467A (en) 1996-12-03 2008-06-27 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1060193A2 (en) 1998-03-03 2000-12-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
OA11917A (en) 1998-12-23 2006-04-13 Abgenix Inc Human monoclonal antibodies to ctla-4.
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
JP2005530490A (en) 2002-03-29 2005-10-13 シェーリング　コーポレイション Human monoclonal antibody and method for interleukin-5 and composition comprising the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895266B2 (en) 2000-10-06 2014-11-25 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell
US9409982B2 (en) 2000-10-06 2016-08-09 Kyowa Hakko Kirin Co., Ltd Antibody composition-producing cell

Also Published As

Publication number Publication date
US7422742B2 (en) 2008-09-09
CA2479927A1 (en) 2003-10-16
MXPA04009418A (en) 2005-06-08
WO2003085089A2 (en) 2003-10-16
JP2005530490A (en) 2005-10-13
ES2327830T3 (en) 2009-11-04
CY1109423T1 (en) 2014-08-13
HK1070907A1 (en) 2005-06-30
CA2479927C (en) 2013-03-12
SI1527100T1 (en) 2009-12-31
CN1326879C (en) 2007-07-18
US20030194404A1 (en) 2003-10-16
DE60328195D1 (en) 2009-08-13
PT1527100E (en) 2009-08-25
JP2010011874A (en) 2010-01-21
EP1527100B1 (en) 2009-07-01
EP1527100A4 (en) 2006-06-14
AU2003220525A8 (en) 2003-10-20
US20070025994A1 (en) 2007-02-01
ATE435239T1 (en) 2009-07-15
CN1656122A (en) 2005-08-17
US7141653B2 (en) 2006-11-28
EP1527100A2 (en) 2005-05-04
DK1527100T3 (en) 2009-09-07
AU2003220525A1 (en) 2003-10-20

Similar Documents

Publication Publication Date Title
WO2003085089A3 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
MY140862A (en) ANTIBODIES TO MAdCAM
AP1918A (en) Antibodies to CD40
AP2072A (en) Antibodies to insulin-like growth factor I receptor
WO2005030124A3 (en) Antibodies to m-csf
WO2006116269A3 (en) Antibodies to myostatin
WO2008019290A3 (en) Human antibodies to erbb 2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NI NO NZ PH PL PT RO RU SC SE SG SK SL TJ TM TN TR TT TZ UA UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2479927

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003582268

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009418

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003716836

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038123975

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003716836

Country of ref document: EP